3
Clinical Trials associated with Romiplostim biosimilar(Intas Biopharmaceuticals Ltd.) / Not yet recruitingPhase 4 A prospective, single-arm, multicentre study to assess safety and efficacy of Romy�® (Romiplostim Powder for Injection) (Intas Pharmaceuticals Ltd., India) in patients with chronic refractory immune (idiopathic) thrombocytopenic purpura (ITP)
A Prospective, Assessor-blind, Randomized, Parallel group Clinical Trial to Assess Single Dose Pharmacokinetics and Pharmacodynamics of Inj. Romiplostim from Intas Pharmaceuticals Ltd. and Inj. Romiplostim of Amgen Inc. in Patients with Chronic Refractory Immune (Idiopathic) Thrombocytopenic Purpura - NA
A Prospective, Open-label, Multi-centric Study to Evaluate the Efficacy and Safety of Inj. Romiplostim of Intas Pharmaceuticals Ltd. in Adult Indian Patients with Chronic Refractory Idiopathic Thrombocytopenic Purpura. - NA
100 Clinical Results associated with Romiplostim biosimilar(Intas Biopharmaceuticals Ltd.)
100 Translational Medicine associated with Romiplostim biosimilar(Intas Biopharmaceuticals Ltd.)
100 Patents (Medical) associated with Romiplostim biosimilar(Intas Biopharmaceuticals Ltd.)
100 Deals associated with Romiplostim biosimilar(Intas Biopharmaceuticals Ltd.)